Asia Pacific Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity
Asia Pacificclinical trials market will grow by 8.4% annually with a total addressable market cap of $97,110.8 million over 2023-2031,
- Bonafide Trust
- 30-04-2023
- Pages : 186
- Figures : 78
- Tables : 96
- Region : Asia-Pacific
- Category : Lifescience
- Medical Devices
Asia Pacific clinical trials market will grow by 8.4% annually with a total addressable market cap of $97,110.8 million over 2023-2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments. Highlighted with 99 tables and 79 figures, this 186-page report “Asia Pacific Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific clinical trials market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country.
What's Inside a Bonafide Research`s industry report?
Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally
Download SampleBased on Product Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Trials of Drugs o Small Molecule Drugs o Vaccines o Cell & Gene Therapy o Other Drugs • Trials of Devices • Trials of Procedures Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Phase I • Phase II • Phase III • Phase IV By Design, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Interventional Studies o Randomized Control Trial o Adaptive Clinical Trial o Non-randomized Control Trial • Observational Studies o Cohort Study o Case Control Study o Cross Sectional Study o Ecological Study • Expanded Access Trials
By Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Protocol Designing • Site Identification • Patient Recruitment • Laboratory Services • Bioanalytical Testing Services • Clinical Trial Data Management Services • Clinical Trial Supply & Logistic Services • Decentralized Clinical Trial Services • Medical Device Testing Services • Other Clinical Trial Services By Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Oncology • Infectious Diseases • Cardiology • Obesity • Diabetes • Neurology • Immunology • Pain Management • Other Indications By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. • Pharmaceutical and Biotechnological Companies • Clinical Research Organizations • Clinical Testing Laboratories • Other End Users
Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031. The breakdown of each national market by Phase, Design, and Indication over the forecast years are also included. The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: Accell Clinical Research LLC Charles River Laboratories ClinDatrix Inc Clinipace Eli Lilly and Company F. Hoffmann-La Roche Ltd. ICON PLC IQVIA Holdings, Inc. Laboratory Corporation of America (Covance Inc.) Novo Nordisk AS PAREXEL International Corporation Pfizer Inc. Pharmaceutical Product Development LLC PhlexAsia Pacific PRA Health Sciences Sanofi SA SGS SA (SGS Life Sciences) Syneos Health Inc. Wuxi AppTec Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
- 1 Introduction 11
- 1.1 Industry Definition and Research Scope 11
- 1.1.1 Industry Definition 11
- 1.1.2 Research Scope 12
- 1.2 Research Methodology 15
- 1.2.1 Overview of Market Research Methodology 15
- 1.2.2 Market Assumption 16
- 1.2.3 Secondary Data 16
- 1.2.4 Primary Data 16
- 1.2.5 Data Filtration and Model Design 17
- 1.2.6 Market Size/Share Estimation 18
- 1.2.7 Research Limitations 19
- 1.3 Executive Summary 20
- 2 Market Overview and Dynamics 23
- 2.1 Market Size and Forecast 23
- 2.1.1 Impact of COVID-19 on World Economy 25
- 2.1.2 Impact of COVID-19 on the Market 28
- 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 30
- 2.2 Major Growth Drivers 34
- 2.3 Market Restraints and Challenges 41
- 2.4 Emerging Opportunities and Market Trends 44
- 2.5 Porter’s Fiver Forces Analysis 48
- 3 Segmentation of Asia Pacific Market by Product Category 52
- 3.1 Market Overview by Product Category 52
- 3.2 Trials of Drugs 54
- 3.2.1 Small Molecule Drugs 55
- 3.2.2 Vaccines 56
- 3.2.3 Cell & Gene Therapy 57
- 3.2.4 Other Drugs 58
- 3.3 Trials of Devices 59
- 3.4 Trials of Procedures 60
- 4 Segmentation of Asia Pacific Market by Phase 61
- 4.1 Market Overview by Phase 61
- 4.2 Phase I 63
- 4.3 Phase II 64
- 4.4 Phase III 65
- 4.5 Phase IV 66
- 5 Segmentation of Asia Pacific Market by Design 67
- 5.1 Market Overview by Design 67
- 5.2 Interventional Studies 69
- 5.2.1 Randomized Control Trial 71
- 5.2.2 Adaptive Clinical Trial 72
- 5.2.3 Non-randomized Control Trial 73
- 5.3 Observational Studies 74
- 5.3.1 Cohort Study 76
- 5.3.2 Case Control Study 77
- 5.3.3 Cross Sectional Study 78
- 5.3.4 Ecological Study 79
- 5.4 Expanded Access Trials 80
- 6 Segmentation of Asia Pacific Market by Service Type 81
- 6.1 Market Overview by Service Type 81
- 6.2 Protocol Designing 83
- 6.3 Site Identification 84
- 6.4 Patient Recruitment 85
- 6.5 Laboratory Services 86
- 6.6 Bioanalytical Testing Services 87
- 6.7 Clinical Trial Data Management Services 88
- 6.8 Clinical Trial Supply & Logistic Services 89
- 6.9 Decentralized Clinical Trial Services 90
- 6.10 Medical Device Testing Services 91
- 6.11 Other Clinical Trial Services 92
- 7 Segmentation of Asia Pacific Market by Indication 93
- 7.1 Market Overview by Indication 93
- 7.2 Oncology 95
- 7.3 Infectious Diseases 96
- 7.4 Cardiology 97
- 7.5 Obesity 98
- 7.6 Diabetes 99
- 7.7 Neurology 100
- 7.8 Immunology 101
- 7.9 Pain Management 102
- 7.10 Other Indications 103
- 8 Segmentation of Asia Pacific Market by End User 104
- 8.1 Market Overview by End User 104
- 8.2 Pharmaceutical and Biotechnological Companies 106
- 8.3 Clinical Research Organizations 107
- 8.4 Clinical Testing Laboratories 108
- 8.5 Other End Users 109
- 9 Asia-Pacific Market 2021-2031 by Country 110
- 9.1 Overview of Asia-Pacific Market 110
- 9.2 Japan 113
- 9.3 China 116
- 9.4 Australia 118
- 9.5 India 120
- 9.6 South Korea 122
- 9.7 Rest of APAC Region 124
- 10 Competitive Landscape 126
- 10.1 Overview of Key Vendors 126
- 10.2 New Product Launch, Partnership, Investment, and M&A 130
- 10.3 Company Profiles 131
- Accell Clinical Research LLC 131
- Charles River Laboratories 133
- ClinDatrix Inc 136
- Clinipace 137
- Eli Lilly and Company 139
- F. Hoffmann-La Roche Ltd. 142
- ICON PLC 145
- IQVIA Holdings, Inc. 148
- Laboratory Corporation of America (Covance Inc.) 152
- Novo Nordisk AS 156
- PAREXEL International Corporation 159
- Pfizer Inc. 163
- Pharmaceutical Product Development LLC 168
- Phlexglobal 171
- PRA Health Sciences 173
- Sanofi SA 175
- SGS SA (SGS Life Sciences) 178
- Syneos Health Inc. 181
- Wuxi AppTec Inc. 184
- RELATED REPORTS 186
Figure 1. Research Method Flow Chart 15
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 18
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2031 20
Figure 4. Asia Pacific Clinical Trials Market, 2021-2031, $ mn 23
Figure 5. Impact of COVID-19 on Business 28
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Clinical Trials Market 34
Figure 7. Percentage of Trial Participants by Country, 2015-2019 37
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million 38
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 39
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060 39
Figure 11. Primary Restraints and Impact Factors of Asia Pacific Clinical Trials Market 41
Figure 12. Investment Opportunity Analysis 45
Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Clinical Trials Market 48
Figure 14. Breakdown of Asia Pacific Clinical Trials Market by Product Category, 2021-2031, % of Revenue 53
Figure 15. Asia Pacific Addressable Market Cap in 2023-2031 by Product Category, Value ($ mn) and Share (%) 53
Figure 16. Asia Pacific Clinical Trials Market by Product Category: Trials of Drugs, 2021-2031, $ mn 54
Figure 17. Asia Pacific Clinical Trials Market by Trials of Drugs: Small Molecule Drugs, 2021-2031, $ mn 55
Figure 18. Asia Pacific Clinical Trials Market by Trials of Drugs: Vaccines, 2021-2031, $ mn 56
Figure 19. Asia Pacific Clinical Trials Market by Trials of Drugs: Cell & Gene Therapy, 2021-2031, $ mn 57
Figure 20. Asia Pacific Clinical Trials Market by Trials of Drugs: Other Drugs, 2021-2031, $ mn 58
Figure 21. Asia Pacific Clinical Trials Market by Product Category: Trials of Devices, 2021-2031, $ mn 59
Figure 22. Asia Pacific Clinical Trials Market by Product Category: Trials of Procedures, 2021-2031, $ mn 60
Figure 23. Breakdown of Asia Pacific Clinical Trials Market by Phase, 2021-2031, % of Sales Revenue 62
Figure 24. Asia Pacific Addressable Market Cap in 2023-2031 by Phase, Value ($ mn) and Share (%) 62
Figure 25. Asia Pacific Clinical Trials Market by Phase: Phase I, 2021-2031, $ mn 63
Figure 26. Asia Pacific Clinical Trials Market by Phase: Phase II, 2021-2031, $ mn 64
Figure 27. Asia Pacific Clinical Trials Market by Phase: Phase III, 2021-2031, $ mn 65
Figure 28. Asia Pacific Clinical Trials Market by Phase: Phase IV, 2021-2031, $ mn 66
Figure 29. Breakdown of Asia Pacific Clinical Trials Market by Design, 2021-2031, % of Sales Revenue 68
Figure 30. Asia Pacific Addressable Market Cap in 2023-2031 by Design, Value ($ mn) and Share (%) 68
Figure 31. Asia Pacific Clinical Trials Market by Design: Interventional Studies, 2021-2031, $ mn 69
Figure 32. Asia Pacific Clinical Trials Market by Interventional Studies: Randomized Control Trial, 2021-2031, $ mn 71
Figure 33. Asia Pacific Clinical Trials Market by Interventional Studies: Adaptive Clinical Trial, 2021-2031, $ mn 72
Figure 34. Asia Pacific Clinical Trials Market by Interventional Studies: Non-randomized Control Trial, 2021-2031, $ mn 73
Figure 35. Asia Pacific Clinical Trials Market by Design: Observational Studies, 2021-2031, $ mn 74
Figure 36. Asia Pacific Clinical Trials Market by Observational Studies: Cohort Study, 2021-2031, $ mn 76
Figure 37. Asia Pacific Clinical Trials Market by Observational Studies: Case Control Study, 2021-2031, $ mn 77
Figure 38. Asia Pacific Clinical Trials Market by Observational Studies: Cross Sectional Study, 2021-2031, $ mn 78
Figure 39. Asia Pacific Clinical Trials Market by Observational Studies: Ecological Study, 2021-2031, $ mn 79
Figure 40. Asia Pacific Clinical Trials Market by Design: Expanded Access Trials, 2021-2031, $ mn 80
Figure 41. Breakdown of Asia Pacific Clinical Trials Market by Service Type, 2021-2031, % of Revenue 82
Figure 42. Asia Pacific Addressable Market Cap in 2023-2031 by Service Type, Value ($ mn) and Share (%) 82
Figure 43. Asia Pacific Clinical Trials Market by Service Type: Protocol Designing, 2021-2031, $ mn 83
Figure 44. Asia Pacific Clinical Trials Market by Service Type: Site Identification, 2021-2031, $ mn 84
Figure 45. Asia Pacific Clinical Trials Market by Service Type: Patient Recruitment, 2021-2031, $ mn 85
Figure 46. Asia Pacific Clinical Trials Market by Service Type: Laboratory Services, 2021-2031, $ mn 86
Figure 47. Asia Pacific Clinical Trials Market by Service Type: Bioanalytical Testing Services, 2021-2031, $ mn 87
Figure 48. Asia Pacific Clinical Trials Market by Service Type: Clinical Trial Data Management Services, 2021-2031, $ mn 88
Figure 49. Asia Pacific Clinical Trials Market by Service Type: Clinical Trial Supply & Logistic Services, 2021-2031, $ mn 89
Figure 50. Asia Pacific Clinical Trials Market by Service Type: Decentralized Clinical Trial Services, 2021-2031, $ mn 90
Figure 51. Asia Pacific Clinical Trials Market by Service Type: Medical Device Testing Services, 2021-2031, $ mn 91
Figure 52. Asia Pacific Clinical Trials Market by Service Type: Other Clinical Trial Services, 2021-2031, $ mn 92
Figure 53. Breakdown of Asia Pacific Clinical Trials Market by Indication, 2021-2031, % of Revenue 94
Figure 54. Asia Pacific Addressable Market Cap in 2023-2031 by Indication, Value ($ mn) and Share (%) 94
Figure 55. Asia Pacific Clinical Trials Market by Indication: Oncology, 2021-2031, $ mn 95
Figure 56. Asia Pacific Clinical Trials Market by Indication: Infectious Diseases, 2021-2031, $ mn 96
Figure 57. Asia Pacific Clinical Trials Market by Indication: Cardiology, 2021-2031, $ mn 97
Figure 58. Asia Pacific Clinical Trials Market by Indication: Obesity, 2021-2031, $ mn 98
Figure 59. Asia Pacific Clinical Trials Market by Indication: Diabetes, 2021-2031, $ mn 99
Figure 60. Asia Pacific Clinical Trials Market by Indication: Neurology, 2021-2031, $ mn 100
Figure 61. Asia Pacific Clinical Trials Market by Indication: Immunology, 2021-2031, $ mn 101
Figure 62. Asia Pacific Clinical Trials Market by Indication: Pain Management, 2021-2031, $ mn 102
Figure 63. Asia Pacific Clinical Trials Market by Indication: Other Indications, 2021-2031, $ mn 103
Figure 64. Breakdown of Asia Pacific Clinical Trials Market by End User, 2021-2031, % of Revenue 104
Figure 65. Asia Pacific Addressable Market Cap in 2023-2031 by End User, Value ($ mn) and Share (%) 105
Figure 66. Asia Pacific Clinical Trials Market by End User: Pharmaceutical and Biotechnological Companies, 2021-2031, $ mn 106
Figure 67. Asia Pacific Clinical Trials Market by End User: Clinical Research Organizations, 2021-2031, $ mn 107
Figure 68. Asia Pacific Clinical Trials Market by End User: Clinical Testing Laboratories, 2021-2031, $ mn 108
Figure 69. Asia Pacific Clinical Trials Market by End User: Other End Users, 2021-2031, $ mn 109
Figure 70. Breakdown of APAC Clinical Trials Market by Country, 2022 and 2031, % of Revenue 111
Figure 71. Contribution to APAC 2023-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 112
Figure 72. Clinical Trials Market in Japan, 2021-2031, $ mn 114
Figure 73. Clinical Trials Market in China, 2021-2031, $ mn 116
Figure 74. Clinical Trials Market in Australia, 2021-2031, $ mn 118
Figure 75. Clinical Trials Market in India, 2021-2031, $ mn 120
Figure 76. Clinical Trials Market in South Korea, 2021-2031, $ mn 122
Figure 77. Clinical Trials Market in Rest of APAC, 2021-2031, $ mn 124
Figure 78. Growth Stage of Asia Pacific Clinical Trials Industry over the Forecast Period 126
Table 1. Snapshot of Asia Pacific Clinical Trials Market in Balanced Perspective, 2022-2031 21
Table 2. Total Number of Registered Clinical Studies Worldwide, 2010-2021 24
Table 3. World Economic Outlook, 2021-2031 26
Table 4. World Economic Outlook, 2021-2023 27
Table 5. Scenarios for Economic Impact of Ukraine Crisis 31
Table 6. World Health Spending by Region, $ bn, 2013-2020 40
Table 7. Main Product Trends and Market Opportunities in Asia Pacific Clinical Trials Market 44
Table 8. Asia Pacific Clinical Trials Market by Product Category, 2021-2031, $ mn 52
Table 9. Asia Pacific Clinical Trials Market: Trials of Drugs by Drug Type, 2021-2031, $ mn 54
Table 10. Asia Pacific Clinical Trials Market by Phase, 2021-2031, $ mn 61
Table 11. Asia Pacific Clinical Trials Market by Design, 2021-2031, $ mn 67
Table 12. Asia Pacific Clinical Trials Market: Interventional Studies by Segment, 2021-2031, $ mn 70
Table 13. Asia Pacific Clinical Trials Market: Observational Studies by Segment, 2021-2031, $ mn 75
Table 14. Asia Pacific Clinical Trials Market by Service Type, 2021-2031, $ mn 81
Table 15. Asia Pacific Clinical Trials Market by Indication, 2021-2031, $ mn 93
Table 16. Asia Pacific Clinical Trials Market by End User, 2021-2031, $ mn 104
Table 17. APAC Clinical Trials Market by Country, 2021-2031, $ mn 111
Table 18. Japan Clinical Trials Market by Phase, 2021-2031, $ mn 115
Table 19. Japan Clinical Trials Market by Design, 2021-2031, $ mn 115
Table 20. Japan Clinical Trials Market by Indication, 2021-2031, $ mn 115
Table 21. China Clinical Trials Market by Phase, 2021-2031, $ mn 117
Table 22. China Clinical Trials Market by Design, 2021-2031, $ mn 117
Table 23. China Clinical Trials Market by Indication, 2021-2031, $ mn 117
Table 24. Australia Clinical Trials Market by Phase, 2021-2031, $ mn 119
Table 25. Australia Clinical Trials Market by Design, 2021-2031, $ mn 119
Table 26. Australia Clinical Trials Market by Indication, 2021-2031, $ mn 119
Table 27. India Clinical Trials Market by Phase, 2021-2031, $ mn 121
Table 28. India Clinical Trials Market by Design, 2021-2031, $ mn 121
Table 29. India Clinical Trials Market by Indication, 2021-2031, $ mn 121
Table 30. South Korea Clinical Trials Market by Phase, 2021-2031, $ mn 123
Table 31. South Korea Clinical Trials Market by Design, 2021-2031, $ mn 123
Table 32. South Korea Clinical Trials Market by Indication, 2021-2031, $ mn 123
Table 33. Clinical Trials Market in Rest of APAC by Country/Region, 2021-2031, $ mn 125
Table 34. Percentage of Registered Studies by Location (as of February 24, 2022) 128
Table 35. Percentage of Recruiting Studies by Location (as of February 24, 2022) 128
Table 36. Accell Clinical Research LLC: Company Snapshot 131
Table 37. Accell Clinical Research LLC: Business Segmentation 132
Table 38. Accell Clinical Research LLC: Product Portfolio 132
Table 39. Charles River Laboratories: Company Snapshot 133
Table 40. Charles River Laboratories: Product Portfolio 134
Table 41. Charles River Laboratories: Breakdown of Revenue by Division 134
Table 42. Charles River Laboratories: Breakdown of Revenue by Region 135
Table 43. ClinDatrix Inc: Company Snapshot 136
Table 44. Clinipace: Company Snapshot 137
Table 45. Clinipace: Product Portfolio 138
Table 46. Eli Lilly and Company: Company Snapshot 139
Table 47. Eli Lilly and Company: Pharmaceutical Brands 140
Table 48. Eli Lilly and Company: Clinical Trial Service 140
Table 49. Eli Lilly and Company: Breakdown of Revenue by Therapeutic Area 140
Table 50. Eli Lilly and Company: Breakdown of Revenue by Region 141
Table 51. F. Hoffmann-La Roche: Company Snapshot 142
Table 52. F. Hoffmann-La Roche: Clinical Trial Service 142
Table 53. F. Hoffmann-La Roche: Business Segmentation 143
Table 54. F. Hoffmann-La Roche: Revenue by Region 143
Table 55. ICON Plc: Company Snapshot 145
Table 56. ICON Plc: Business Segmentation 145
Table 57. ICON Plc: Product Portfolio 146
Table 58. ICON Plc: Revenue by Region, 2020, % 146
Table 59. IQVIA Holdings Inc.: Company Snapshot 148
Table 60. IQVIA Holdings Inc.: Business Segmentation 149
Table 61. IQVIA Holdings Inc.: Revenue by Region, 2020, % 149
Table 62. IQVIA Holdings Inc.: Product Portfolio 150
Table 63. Covance Inc.: Company Snapshot 152
Table 64. Covance Inc.: Product Portfolio 153
Table 65. Covance Inc.: Revenue by Region, 2020, % 154
Table 66. Novo Nordisk: Company Snapshot 156
Table 67. Novo Nordisk: Product Portfolio 157
Table 68. Novo Nordisk: Breakdown of Revenue by Business Segment 158
Table 69. Novo Nordisk: Breakdown of Revenue by Region 158
Table 70. PAREXEL International Corporation: Company Snapshot 159
Table 71. PAREXEL International Corporation: Business Segmentation 160
Table 72. PAREXEL International Corporation: Revenue by Region, 2018, % 160
Table 73. PAREXEL International Corporation: Product Portfolio 161
Table 74. Pfizer Inc.: Company Snapshot 163
Table 75. Pfizer Inc.: Business Segmentation 164
Table 76. Pfizer Inc.: Breakdown of Revenue by Product Category 164
Table 77. Pfizer Inc.: Breakdown of Revenue by Region 165
Table 78. Pfizer Inc.: Product Portfolio 165
Table 79. Pfizer Inc.: Revenue, 2018-2020, $ bn 166
Table 80. Pharmaceutical Product Development LLC (PPD): Company Snapshot 168
Table 81. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Division 169
Table 82. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Region 169
Table 83. Phlexglobal: Company Snapshot 171
Table 84. PRA Health Sciences Inc.: Company Snapshot 173
Table 85. PRA Health Sciences Inc.: Business Segmentation 174
Table 86. PRA Health Sciences Inc.: Revenue by Region, 2018, % 174
Table 87. Sanofi: Company Snapshot 175
Table 88. Sanofi: Business Segmentation 176
Table 89. Sanofi: Breakdown of Revenue by Region 176
Table 90. SGS SA (SGS Life Sciences): Company Snapshot 178
Table 91. SGS SA (SGS Life Sciences): Business Segmentation 179
Table 92. SGS SA (SGS Life Sciences): Revenue by Region, 2018, % 179
Table 93. Syneos Health Inc.: Company Snapshot 181
Table 94. Syneos Health Inc.: Business Segmentation 182
Table 95. Syneos Health Inc.: Revenue by Region, 2020, % 182
Table 96. WuXi AppTec Inc.: Company Snapshot 184
Related Reports
Allows one individual to access the purchased report Read More
Allows all employees of an organization to access the purchased report. Internal sharing only Read More
Allows all employees of an organization to access the purchased report. It also permits the use of up to 4 paragraphs or 1 page of the report externally in whitepapers, press releases, and marketing collateral Read More
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (27 July, 2024)
- Notify To Team (27 July, 2024)
- Report updation (28 July, 2024)
- Report Quality Check (28 July, 2024)
- Report Dispatch (29 July, 2024)
- Hard Copy
Recently Viewed Products
Asia Pacific Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity
We are friendly and approachable, give us a call.